[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2419
1. Savu A, Potter J, Li S, Yasui Y: Breast cancer and microbial cancer incidence in female populations around the world: a surprising hyperbolic association. Int J Cancer; 2008 Sep 1;123(5):1094-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We showed previously an unexpected very high positive correlation between breast cancer (BC) and young-adult Hodgkin disease incidence rates.


2. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM: Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood; 2008 Apr 1;111(7):3377-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma.
  • Young adult Hodgkin lymphoma (YAHL) is associated clinically with altered immunity, including a systemic defect in cell-mediated responses.
  • We identified twin pairs in whom at least one member had YAHL and measured interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-gamma) levels in PHA-stimulated peripheral blood mononuclear cell supernatant in 90 case-twins, 84 of their disease-free twins (unaffected cotwins), and 90 matched controls.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Oct 15;175(8):5457-62 [16210653.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Genes Immun. 2000 Dec;1(8):515-20 [11197695.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):218-21 [11175794.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Twin Res. 2001 Aug;4(4):242-50 [11665304.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):69-75 [11905816.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):545-52 [12845650.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Biometrics. 1982 Sep;38(3):715-24 [7171697.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):673-82 [2251514.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):174-7 [8700209.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1658-65 [9257825.001]
  • [Cites] Genes Immun. 2004 Dec;5(8):675-7 [15483662.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1432-6 [15603869.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):740-8 [15643599.001]
  • [Cites] Genes Immun. 2005 Mar;6(2):167-70 [15674372.001]
  • [Cites] Intensive Care Med. 2005 Mar;31(3):401-7 [15719148.001]
  • [Cites] Cytokine. 2005 May 21;30(4):188-94 [15863393.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):125-35 [16510856.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2062-3 [16990781.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • (PMID = 18077789.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2275007
  •  go-up   go-down


3. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


Advertisement
4. Yayan J, Mallouhi A, Moser P, Irschick E: [Non-Hodgkin lymphoma of the lacrimal gland]. Ophthalmologe; 2008 Sep;105(9):852-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma of the lacrimal gland].
  • [Transliterated title] Non-Hodgkin-Lymphom der Tränendrüse.
  • BACKGROUND: Non-Hodgkin lymphoma is a systemic disease and various organs can therefore be affected.
  • Ocular manifestations of non-Hodgkin lymphomas are possible but involvement of the eyelids or lacrimal glands are uncommon.
  • The histologic examination revealed a recurrent non-Hodgkin lymphoma.
  • In the case described here it was interesting that behind a painless eyelid swelling even a systemic disorder was hidden, i.e. a recurrence of a non-Hodgkin lymphoma, which was localized in the lacrimal gland.
  • [MeSH-major] Eye Neoplasms. Lacrimal Apparatus. Lymphoma, Follicular
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Diagnosis, Differential. Edema / etiology. Eyelid Diseases / etiology. Female. Humans. Immunotherapy. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Rituximab. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2007 Aug;86(8):565-8 [17483948.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 Apr;221(4):266-72 [15118956.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):863-8 [15270618.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1451-60 [16638927.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Br J Ophthalmol. 2006 Aug;90(8):936-7 [16854834.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Curr Opin Ophthalmol. 2006 Dec;17(6):523-31 [17065920.001]
  • [Cites] Eye (Lond). 2006 Oct;20(10):1186-8 [17019417.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Br J Ophthalmol. 1988 Apr;72 (4):248-52 [3288277.001]
  • [Cites] Ophthalmologe. 1994 Jun;91(3):357-63 [8086753.001]
  • (PMID = 18373097.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


5. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


6. Freed J, Kelly KM: Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs; 2010 Apr 01;12(2):85-98
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approaches to the management of pediatric Hodgkin lymphoma.
  • Hodgkin lymphoma is one of the few cancers that affect both adults and children.
  • Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers.
  • At diagnosis, patients are classified into risk groups based on disease stage, and the presence of clinical, biologic, and serologic risk factors.
  • In general, the most recent trials have intensified therapy in those patients with high-risk disease to improve disease control, and have limited therapy in those patients with low-risk disease to avoid secondary effects.
  • In addition, response assessment by fluorine-18-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) may be particularly important in pediatric Hodgkin lymphoma; it may allow modification of treatment to maximize treatment efficacy and minimize late effects of chemotherapy and radiation therapy.
  • Despite the improvements in treatment for all stages of Hodgkin lymphoma, there is still a subgroup of patients who do not enter remission with initial therapy or relapse after initial response to therapy.
  • Unfortunately, standard-dose salvage chemotherapy for relapsed disease has disappointing results in terms of overall survival since patients have typically already received intensive therapy.
  • While there is no standard of care in terms of salvage chemotherapy, high-dose chemotherapy with autologous stem cell transplant (ASCT) rescue has become the standard of care for the majority of children with relapsed Hodgkin lymphoma.
  • The use of allogeneic transplantation is controversial in relapsed or refractory Hodgkin lymphoma; because of the high transplant-related mortality, allogeneic transplant has not been associated with improved overall survival over ASCT.
  • As more has been learned about the biologic mechanisms involved in Hodgkin lymphoma, biologically-based therapies are being investigated for use in this disease, both at initial diagnosis and relapse.
  • Both immunotherapy and small molecules are being studied as possible therapeutic agents in Hodgkin lymphoma.
  • Unfortunately, the vast majority of investigations of novel agents have occurred exclusively in adult patients.
  • However, since pediatric Hodgkin lymphoma and adult Hodgkin lymphoma are similar, these results may potentially be extrapolated to pediatric Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Neoplasm Staging. Remission Induction / methods. Risk Factors. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):62-8 [14657226.001]
  • [Cites] Ann Hematol. 1994 Mar;68(3):105-10 [8167175.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1209-18 [11728679.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1313-9 [17613759.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jul;43(1):8-16 [15170884.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):230-42 [17591570.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4669-78 [16034043.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):519-25 [9324338.001]
  • [Cites] Ann Oncol. 1990;1(2):123-7 [1706614.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):332-7 [17235049.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 May;24(4):269-73 [11972094.001]
  • [Cites] Curr Treat Options Oncol. 2007 Oct;8(5):352-74 [18214690.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):26-34 [16161019.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1370-7 [12196362.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2390-6 [11331317.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2051-9 [19584400.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:107-11 [12078889.001]
  • [Cites] N Engl J Med. 1990 Jan 4;322(1):7-13 [2403650.001]
  • [Cites] Exp Hematol. 2002 Apr;30(4):285-96 [11937262.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):493-500 [17290056.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1456-61 [19224841.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3736-44 [10577845.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6181-9 [16135485.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2764-9 [17515574.001]
  • (PMID = 20218745.001).
  • [ISSN] 1179-2019
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 73
  •  go-up   go-down


7. Otrock ZK, Shamseddine AI, Taher AT: Non-Hodgkin disease in beta-thalassemia major. Am J Hematol; 2006 Jan;81(1):62-4
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin disease in beta-thalassemia major.
  • The occurrence of lymphoma in thalassemia has rarely been reported, and our review of the English literature revealed only four cases.
  • Because anemia is always masked by regular transfusions in thalassemic patients, physicians discover a hidden malignancy late in the course of the disease.
  • We hereby report the case of a thalassemic patient developing non-Hodgkin disease and discuss the possibility of a link between the two disease entities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. beta-Thalassemia
  • [MeSH-minor] Adult. Child. Child, Preschool. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Female. Humans. Infant. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thalassemia.
  • Genetic Alliance. consumer health - Beta Thalassemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16369971.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCOP protocol
  •  go-up   go-down


8. Kilani B, Ammari L, Tiouiri H, Kanoun F, Ben Romdhane K, Ben Chaabane T: [Transverse myelitis revealing Hodgkin disease]. Presse Med; 2006 Apr;35(4 Pt 1):615-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transverse myelitis revealing Hodgkin disease].
  • [Transliterated title] Myélite transverse révélant une maladie de Hodgkin.
  • INTRODUCTION: Neurological complications during Hodgkin disease are rare and sometimes difficult to diagnose.
  • DISCUSSION: The variable neurological events observed during Hodgkin disease may serve to reveal this disease.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Myelitis, Transverse / complications. Myelitis, Transverse / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Myelitis.
  • Genetic Alliance. consumer health - Transverse myelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614604.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Illés A: [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience]. Orv Hetil; 2010 Jan 31;151(5):172-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience].
  • [Transliterated title] Refrakter és relabált Hodgkin-lymphomás betegeink kezelésével szerzett tapasztalataink.
  • Recovery have been achieved in the majority of Hodgkin-lymphoma patients.
  • AIM AND METHODS: We investigated the frequency and treatment of refracter or relapsed Hodgkin lymphoma patients between 1996 and 2006.
  • 6 of the relapsed patients were died, 5 because of the progression of lymphoma and one because of secunder myelodysplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Recurrence. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083465.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


10. Dögel D, Beuing O, Koenigsmann M, Diete S: [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr; 2008 Jan;76(1):41-6
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
  • [Transliterated title] Paraneoplastische Limbische Enzephalitis als Erstmanifestation eines malignen Non Hodgkin Lymphoms.
  • Paraneoplastic limbic encephalitis (PLE) is a rare disease that is probably caused by an immunological reaction against CNS-structures.
  • Besides treatment of the underlying neoplastic disease, there is no generally applicable evidence-based treatment.
  • PLE is most frequently associated with certain carcinomas, but its occurrence with Hodgkin lymphoma has also been recognized.
  • Association with non-Hodgkin lymphoma has only been occasionally reported in single cases.
  • We report two additional patients, in whom malignant non-Hodgkin lymphomas of the B- and T-cell lines were detected.
  • [MeSH-major] Limbic Encephalitis / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189222.001).
  • [ISSN] 0720-4299
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


11. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


12. Molnár Z, Simon Z, Borbényi Z, Deák B, Galuska L, Keresztes K, Miltényi Z, Marton I, Rosta A, Schneider T, Trón L, Várady E, Illés A: [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results]. Orv Hetil; 2009 Nov 22;150(47):2133-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results].
  • [Transliterated title] Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink.
  • In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Radiopharmaceuticals. Recurrence. Remission Induction. Retrospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910278.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ: Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol; 2009 May 20;27(15_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
  • : 8547 Background: Increased late mortality and morbidity have been observed among adult survivors of Hodgkin lymphoma (HL) treated in childhood, but are less well characterized for patients treated in adulthood.
  • METHODS: We investigated the late mortality and morbidity of adult patients treated at our center from 1975 to 2000.
  • The most prevalent severe morbidities included second primary malignancy (SPM) (17%), cardiovascular (CV) (18%) and neurologic (18%) disease.
  • CONCLUSIONS: Among adults treated on trials of CMT, by 22y post-treatment the risk of death due to HL is surpassed by risk of death due to other causes.
  • These findings underscore the importance of efforts directed at prevention of and early intervention for late morbidity in adult survivors of HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • 8 patients (32%) had stable disease and 12 (48%) progressed on treatment.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • It can mitigate symptoms resulting from bulky disease and shows potential as a palliative treatment option.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Jóna A, Illés A: [Changing patterns in the clinical, pathological features of Hodgkin lymphoma]. Orv Hetil; 2010 Dec 5;151(49):2011-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing patterns in the clinical, pathological features of Hodgkin lymphoma].
  • [Transliterated title] Változnak-e a Hodgkin-lymphoma klinikopatológiai jellemzői?
  • Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
  • PATIENTS AND METHODS: The Authors analyzed 439 Hodgkin lymphoma patients' clinicopathological and treatment data.
  • RESULTS: The first period contained 117 patients, the second 147 and third 115 Hodgkin lymphoma patients.
  • CONCLUSIONS: Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Socioeconomic Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21106481.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


17. Beck Z, Illés A, Keresztes K, Bessenyei B, Szöllosi Z, Kis A, Oláh E: [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?]. Orv Hetil; 2006 Aug 20;147(33):1539-44
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
  • [Transliterated title] Az Epstein-Barr-vírus ZEBRA fehérjéjének expressziója magyarországi Hodgkin-lymphomás betegekben: latens vagy litikus ciklus?
  • The virus is associated with an increasing number of lymphoid malignancies, such as Hodgkin and non-Hodgkin lymphomas.
  • Although the presence of ZEBRA protein induces lytic cycle, some lymphoma cases show this protein expression.
  • AIM: In our present study we investigated the frequency of expression of ZEBRA protein in Hungarian patients with Hodgkin lymphoma associated with Epstein-Barr virus infection.
  • The authors wanted to clarify whether this expression is specific to latency type II or occurs in some non-Hodgkin lymphoma cases with latency type III as well.
  • We detected the weak expression of ZEBRA protein in 13 of the 25 LMP1 positive Hodgkin lymphoma cases and in 6 of the 18 LMP1 positive non-Hodgkin lymphoma samples.
  • CONCLUSION: In the examined group of patients the ZEBRA positivity associated with a poor prognosis of the disease.
  • [MeSH-major] DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / virology. Trans-Activators / analysis. Viral Proteins / analysis
  • [MeSH-minor] Adult. Aged. Epstein-Barr Virus Nuclear Antigens / analysis. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Hungary. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037676.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA-Binding Proteins; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  •  go-up   go-down


18. Keresztes K, Bessenyei B, Szöllosi Z, Beck Z, Miltényi Z, Nemes Z, Oláh E, Illés A: [Association of Hodgkin lymphoma with Epstein-Barr virus in Hungary]. Orv Hetil; 2005 Jul 24;146(30):1575-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of Hodgkin lymphoma with Epstein-Barr virus in Hungary].
  • [Transliterated title] Hodgkin-lymphomfás betegek Epstein-Barr-virus-asszociációjának vizsgálata.
  • INTRODUCTION: The occurrence of Epstein-Barr virus associated Hodgkin's lymphoma shows considerable variation from continent to continent and from country to country but in Hungary no such investigations have been performed so far.
  • AIM: The authors analyse the presence of Epstein-Barr virus and the type of latency in histologic samples taken from Hodgkin's disease patients.
  • Epstein-Barr virus association did not show any alteration in children (1-14 years) when compared to that of adults (out of the 10 children 6 were positive by PCR).
  • On examining Hodgkin's lymphoma and Epstein-Barr virus association disease models, they could not categorize their patients into any of them though characteristic patient groups could be more or less observed also in their material.
  • CONCLUSION: These results indicate that Epstein-Barr infection may play an important role in the development of Hodgkin's lymphoma in Hungary, too.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Hungary / epidemiology. Immunohistochemistry. In Situ Hybridization. Infant. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136734.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


19. Negri E: Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma. Nutr Cancer; 2010;62(7):878-82
MedlinePlus Health Information. consumer health - Vitamin D.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma.
  • Similarities in the epidemiology of melanoma, other skin cancers, and non-Hodgkin lymphoma (NHL) have led to the hypothesis that UV exposure, the major risk factor for cutaneous cancers, could play a role on NHL risk too.
  • The paucity of information on the relation of sun exposure or vitamin D with adult Hodgkin lymphoma (HL) or childhood lymphomas prevents any definite conclusion.
  • [MeSH-major] Lymphoma, Non-Hodgkin / etiology. Sunlight / adverse effects. Vitamin D / analogs & derivatives
  • [MeSH-minor] Disease Susceptibility. Humans. Risk Factors. SEER Program

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924963.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D
  •  go-up   go-down


20. Wilson KS, Gallagher A, Freeland JM, Shield LA, Jarrett RF: Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies. Leuk Lymphoma; 2006 Jul;47(7):1315-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies.
  • The epidemiology of young adult Hodgkin lymphoma (HL) suggests that delayed exposure to a common childhood pathogen may be involved in disease pathogenesis.
  • The Epstein-Barr virus (EBV) is associated with a proportion of cases but cases of young adult HL in westernized countries are less frequently EBV-associated than cases in other age groups and geographical locales.
  • [MeSH-major] Genome, Viral. Hodgkin Disease / virology. Polyomavirus / genetics
  • [MeSH-minor] Adult. Aged. Biopsy. DNA Primers / chemistry. Female. Herpesvirus 4, Human / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY911513
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


21. Viscasillas Pallás G, Cisa Lluís E, Cruellas Taischik F, Doménech Juan I, Dicenta Sousa M: [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma]. An Otorrinolaringol Ibero Am; 2005;32(1):23-8
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma].
  • [Transliterated title] Actinomicosis cervical versus linfoma de Hodgkin. A propósito de un caso.
  • We present the case of a young patient affected by a cervical tumoration initially oriented as Hodgkin lymphoma that finally was diagnosed as cervical actinomycosis and treated with penicillin.
  • [MeSH-major] Actinomycosis / diagnosis. Actinomycosis / microbiology. Cervical Vertebrae / microbiology. Hodgkin Disease / diagnosis. Propionibacterium / isolation & purification
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed


22. Halilbasić A, Mesic E, Cikusić E, Arnautović A: [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]. Med Arh; 2006;60(6 Suppl 2):78-83
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease].
  • [Transliterated title] Non Hodgkin limfom u Sjeveroistoinoj Bosni--promjene u bioloskoj agresivnosti i nacinu primarne prezentacije.
  • These factors were analysed: immunophenotype NHL by immunohistochemical method of indirect three-stage immunoperoxidase with streptovidin, the type of NHL, the degree of biological aggressiveness of NHL, the way of primary presentation and the clinical phases of distribution of the disease according to the age, sex, profession and the habitat (urban or rural) of the patients.
  • The prevalence and the incidence of the disease in the region of the North-East Bosnia was determined.
  • Diffuse Large Cell Lymphoma (DLCL) was dominant in the test group with total of 73 patients (51%), and Small Cell Lymphoma was dominant in the control group with total of 33 patients (38%).
  • Statistically significant increase of both DLCL and MALT lymphoma is found in the test group (p < 0.025), and the most frequent were patients with IV-B (18%), I-AE (15%) and II-BE (12%) clinical stadium, while in the control group the most frequent number of patients was in the clinical studia III-B (19%), II-B (14%) and IV-B (14%).
  • In the test group there was a significant increase of aggressive lymphoma in both men and women (p < 0.01).
  • In the test group the number of MALT and DLCL lymphoma located in stomach is in increase.
  • Therefore the significant increase of the patients with this disease is noticed in our test group.
  • CONCLUSION: The incidence of NHL in the region of the North East Bosnia follows the world trend of the general increase of the NHL incidence including the significant increase in number of aggressive lymphoma.
  • The frequency of DLCL and MALT lymphoma is evidently in increase.
  • The significant changes in primary presentation of the disease have not been noticed.
  • [MeSH-major] Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Bosnia and Herzegovina / epidemiology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172989.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


23. Kochbati L, Chraïet N, Nasr C, Boussen H, Touati S, Ben Romdhane K, Maalej M: [Hodgkin disease of the nasopharynx: report of three cases]. Cancer Radiother; 2006 May;10(3):142-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin disease of the nasopharynx: report of three cases].
  • [Transliterated title] Maladie de Hodgkin du cavum: à propos de trois cas.
  • We report three cases of Hodgkin's disease (HD) involving the nasopharynx.
  • Histological study showed mixed cellularity type of HD in all cases.
  • HD of nasopharynx should be differentiated from EBV-associated lymphoproliferations.
  • [MeSH-major] Hodgkin Disease. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309942.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Möller P, Mader A, Barth TF, Brüderlein S: [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma]. Pathologe; 2008 Nov;29 Suppl 2:317-8
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma].
  • [Transliterated title] U-HO1. Eine neue Zelllinie, abstammend von einem primär therapierefraktären klassischen Hodgkin-Lymphom.
  • The Hodgkin cell line U-HO1 was established from a malignant pleural effusion of a 23-yr-old male patient during the end stage of refractory nodular sclerosing classical Hodgkin lymphoma (cHL).
  • [MeSH-major] Cell Line, Tumor. Hodgkin Disease / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Allelic Imbalance / genetics. Cell Division / genetics. Cell Division / physiology. Chromosomes, Human, Pair 2 / genetics. Combined Modality Therapy. Drug Resistance, Neoplasm / genetics. HLA-D Antigens / analysis. Humans. Male. Phenotype. Reed-Sternberg Cells / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Feb;17(2):416-26 [12592342.001]
  • [Cites] Ann N Y Acad Sci. 2003 Apr;987:173-9 [12727637.001]
  • [Cites] Cytogenet Genome Res. 2007;119(3-4):204-10 [18253030.001]
  • [Cites] Blood. 1994 Aug 1;84(3):708-15 [8043859.001]
  • (PMID = 18820924.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA-D Antigens
  •  go-up   go-down


25. Miltényi Z, Keresztes K, Ujhelyi L, Kovács J, Illés A: [Nephrotic syndrome in Hodgkin's disease]. Orv Hetil; 2005 Jun 19;146(25):1357-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephrotic syndrome in Hodgkin's disease].
  • [Transliterated title] Nephrosis szindrómával járó Hodgkin-kór.
  • The authors are presenting a rare paraneoplastic syndrome in Hodgkin's disease.
  • Four months later, when the nephrosis syndrome relapsed, Hodgkin's disease was diagnosed (nodular sclerosing subtype).
  • Hodgkin's disease was staged as III/BS.
  • Polychemotherapy resulted complete remission of both Hodgkin's disease and nephrotic syndrome.
  • Causes of nephrotic syndrome in Hodgkin's disease can include renal vein thrombosis, amyloidosis or paraneoplastic syndrome.
  • Nephrotic syndrome in Hodgkin's disease may relate to dysfunction of T-cells or altered cytokine balance, but the exact pathogenesis is not known.
  • This case attracts attention that a rare cause of nephrotic syndrome can be Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Nephrotic Syndrome / diagnosis. Nephrotic Syndrome / etiology. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Glomerulonephritis / diagnosis. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106759.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


26. Msaad S, Yangui I, Ketata W, Ayoub A, Ayedi H: [Tracheal involvement revealing Hodgkin's disease. A case report]. Rev Pneumol Clin; 2007 Oct;63(5 Pt 1):323-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tracheal involvement revealing Hodgkin's disease. A case report].
  • [Transliterated title] Atteinte trachéale révélatrice d'une maladie de Hodgkin.
  • Inaugural tracheobronchitis is a rare but known manifestation of Hodgkin's disease.
  • We report a case of Hodgkin's disease revealed by wheezing with minimal hemoptysis.
  • Histology of the endoscopic biopsies demonstrated Hodgkin type infiltration of the trachea with mixed cellularity.
  • [MeSH-major] Hodgkin Disease / diagnosis. Tracheal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bleomycin / therapeutic use. Bronchoscopy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Neoplasm Staging. Radiography, Thoracic. Radiotherapy Dosage. Remission Induction. Respiratory Sounds / etiology. Time Factors. Tomography, X-Ray Computed. Trachea / pathology. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166936.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


27. Herbertson R, Hancock BW: Hodgkin Lymphoma in adolescents. Cancer Treat Rev; 2005 Aug;31(5):339-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin Lymphoma in adolescents.
  • With the development of an integrated treatment approach, the cure rate and survival of patients with Hodgkin Lymphoma (HL) is now high.
  • Future treatment strategies may direct the treatment of adolescents with HL away from the current "adult" regimens, and closer to that currently received by children, but prospective randomised trials are required.
  • [MeSH-major] Hodgkin Disease

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951118.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


28. Müller J, Molnár Z, Illés A, Csóka M, Jakab Z, Deák B, Schneider T, Várady E, Rosta A, Simon Z, Keresztes K, Gergely L, Kovács G: [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?]. Orv Hetil; 2008 Nov 23;149(47):2221-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?].
  • [Transliterated title] Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: felnôtt- vagy gyermekintézményben?
  • Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards.
  • AIM: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes.
  • METHODS: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P).
  • Event-free survival was higher in pediatric than in adult institutes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Care Facilities / statistics & numerical data. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Hungary / epidemiology. Male. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004744.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; OPPA protocol
  •  go-up   go-down


29. Steiropoulos P, Kouliatsis G, Karpathiou G, Popidou M, Froudarakis ME: Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas. Respiration; 2009;77(4):459-63
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas.
  • Primary pleural lymphoma is rare.
  • It occurs in only 7% of lymphoma cases.
  • We report herein two cases of primary pleural Hodgkin and non-Hodgkin follicular lymphomas diagnosed by thoracoscopy under local anesthesia.
  • The pleural findings during thoracoscopy differed in the two cases and selective pleural biopsies under optical forceps led to the diagnosis of lymphoma.
  • To date, primary pleural Hodgkin and non-Hodgkin follicular lymphomas have not been reported.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Follicular / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Dyspnea / etiology. Female. Humans. Male. Middle Aged. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18503251.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Azim HA Jr, Pruneri G, Cocorocchio E, Cinieri S, Raviele PR, Bassi S, Preda L, Martinelli G, Peccatori FA: Rituximab in lymphocyte-predominant Hodgkin disease. Oncology; 2009;76(1):26-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in lymphocyte-predominant Hodgkin disease.
  • BACKGROUND: Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic Hodgkin disease.
  • At a median follow-up of 2 years, 4 patients are still disease free while the rest relapsed at a median time of 27 months.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033694.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


31. Benharroch D, Einav I, Feldman A, Levy A, Ariad S, Gopas J: Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited. APMIS; 2010 May;118(5):339-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited.
  • We scrutinized the role of apoptosis of the Hodgkin-Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) and critically reviewed its features in the light of conflicting evidence.
  • These findings support our contention that the role of apoptosis in the HRS cells of Hodgkin lymphoma has not been completely elucidated and is at variance with that in the consensus.
  • [MeSH-major] Apoptosis / physiology. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Herpesvirus 4, Human / metabolism. Herpesvirus 4, Human / pathogenicity. Humans. Immunohistochemistry. Male. Middle Aged. NF-kappa B / metabolism. Viral Matrix Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477808.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  • [Number-of-references] 29
  •  go-up   go-down


32. Lechner K, Chen YA: Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma. Leuk Lymphoma; 2010 Mar;51(3):469-74
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma.
  • We assessed the occurrence, clinical, and laboratory features as well as the response to treatment of autoimmune hemolytic anemia, autoimmune thrombocytopenia, and neutropenia in published cases of Hodgkin lymphomas (HL).
  • The autoimmune cytopenias (AIC) may occur prior to, concurrent with, at the time of recurrence of lymphoma or in complete remission after treatment.
  • HL is the only lymphoma which may be associated with autoimmune neutropenia.
  • In contrast to AIC in diffuse large B-cell lymphoma (DLBCL), early stage is less common in patients with HL with AIC.
  • [MeSH-major] Autoimmune Diseases / complications. Hodgkin Disease / complications. Neutropenia / complications. Thrombocytopenia / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. PubMed. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141438.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


33. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT: CNS Hodgkin lymphoma. Blood; 2008 Sep 1;112(5):1658-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS Hodgkin lymphoma.
  • Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare.
  • Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse.
  • Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Middle Aged. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] Radiat Med. 2000 May-Jun;18(3):205-8 [10972552.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):387-8; 393 [11414479.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1667-71 [15370222.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3182 [17634503.001]
  • [Cites] Cancer. 1979 Apr;43(4):1497-506 [376094.001]
  • [Cites] Cancer. 1983 Oct 1;52(7):1301-7 [6883291.001]
  • [Cites] Clin Lab Haematol. 1989;11(4):331-8 [2605874.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1437-8 [17416864.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4228-30 [15483035.001]
  • (PMID = 18591379.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710443
  •  go-up   go-down


34. Díez L, Guijarro IG, Vaamonde P, Fernández P: [Primary manifestation of Hodgkin lymphoma in adenoid. About a case]. Acta Otorrinolaringol Esp; 2010 Nov-Dec;61(6):462-4
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary manifestation of Hodgkin lymphoma in adenoid. About a case].
  • [Transliterated title] Manifestación primaria de linfoma de Hodgkin en adenoides. A propósito de un caso.
  • Hodgkin's disease (HD) accounts for only 10-35% of all cases, where the lymph node is affected in 70-80%.
  • We present the case of a patient with HD with extranodal involvement, given the rarity of this entity.
  • [MeSH-major] Adenoids. Hodgkin Disease / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Adenoids.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20092806.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


35. Paes FM, Kalkanis DG, Sideras PA, Serafini AN: FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics; 2010 Jan;30(1):269-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
  • The term extranodal disease refers to lymphomatous infiltration of anatomic sites other than the lymph nodes.
  • Almost any organ can be affected by lymphoma, with the most common extranodal sites of involvement being the stomach, spleen, Waldeyer ring, central nervous system, lung, bone, and skin.
  • The prevalence of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease has increased in the past decade.
  • More recently, hybrid PET/CT has become the standard imaging modality for initial staging, follow-up, and treatment response assessment in patients with lymphoma and has proved superior to CT in these settings.
  • Certain PET/CT patterns are suggestive of extranodal disease and can help differentiate tumor from normal physiologic FDG activity, particularly in the mucosal tissues, bone marrow, and organs of the gastrointestinal tract.
  • In addition, a knowledge of the differences in FDG avidity among the histologic subtypes of lymphoma, appropriate timing of scanning after therapeutic interventions, and use of techniques to prevent brown fat uptake are essential for providing the oncologist with accurate information.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Subtraction Technique. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083598.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Mlczoch L, Attarbaschi A, Dworzak M, Gadner H, Mann G: Alopecia areata and multifocal bone involvement in a young adult with Hodgkin's disease. Leuk Lymphoma; 2005 Apr;46(4):623-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alopecia areata and multifocal bone involvement in a young adult with Hodgkin's disease.
  • Staging procedures revealed multifocal bone disease and generalized lymphadenopathy.
  • The diagnosis of nodular sclerosing Hodgkin's disease was established by biopsies of the os ileum and a left inguinal lymph node.
  • Conclusively, this case illustrates that alopecia areata may occur as a paraneoplastic phenomenon or an autoimmune process related to the deranged cellular immune system in children and adolescents with Hodgkin's disease.
  • [MeSH-major] Alopecia Areata / complications. Bone Neoplasms / complications. Hodgkin Disease / complications

  • Genetic Alliance. consumer health - Alopecia Areata.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019495.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Sánchez-Salmón A, Barandela J, Garrido M, Ciobotaru AB, Albo C, Ruibal A: [Evolution in 18F-FDG-PET of a case of Hodgkin disease, nodular sclerosis variety, after treatment and autotrasplant]. Rev Esp Med Nucl; 2007 May-Jun;26(3):165-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution in 18F-FDG-PET of a case of Hodgkin disease, nodular sclerosis variety, after treatment and autotrasplant].
  • [Transliterated title] Evolución, mediante estudios con 18F-FDG, de un caso de enfermedad de Hodgkin tipo esclerosis nodular después de tratamiento y autotrasplante.
  • Positron Emission Tomography (PET) has become a very useful tool for monitoring Hodgkin's disease patients in the last years.
  • When there is suspicion of disease persistence after treatment, this technique makes it possible to evaluate treatment activity of the residual lesions observed in the CT scan.
  • We present the case of a woman with Hodgkin's disease in which 18F-FDG PET was included in the follow-up.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Pneumonia / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Whole Body Imaging
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Lymph Nodes / radionuclide imaging. Mechlorethamine / administration & dosage. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Tomography, X-Ray Computed. Transplantation, Autologous. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524311.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


38. Yi WS, Xu XL, Xiang Q, Jiang HB: [Characteristics of ocular adnexal non-Hodgkin lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;33(9):826-30
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of ocular adnexal non-Hodgkin lymphoma].
  • OBJECTIVE: To investigate the clinical manifestation and pathological features of primary ocular adnexal non-Hodgkin lymphoma.
  • METHODS: Data of 18 patients with biopsy-proven ocular adnexal non-Hodgkin lymphoma at Xiangya hospital were reviewed.The disease site, clinical manifestation,imaging and pathological features of the tumor were summarized.
  • RESULTS: All patients had typical presentation of an adnexal mass.Twelve(66.7%) patients had orbital involvement, 3(16.7%) had conjunctival, and 3(16.7%) had lymphoma involving the eyelids.Eight patients were misdiagnosed as "inflammatory pseudotumour" before the operation according to their clinical and imaging examination,another 8 patients were diagnosed as "ocular adnexal tumour with unknown nature" before the operation.
  • According to the pathologic diagnosis, 16 patients (88.9%)had marginal zone lymphomas of mucosa-associated lymphoid tissue(MZL-MALT) and 2 (11.1%) had NK/T-cell lymphoma.
  • CONCLUSION: The typical presentation of ocular adnexal lymphoma is a painless mass.Orbital connective tissue is the most involved anatomical site.
  • The diagnosis of ocular adnexal non-Hodgkin lymphoma is difficult which could easily be misdiagnosed as "inflammatory pseudotumour".
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812662.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


39. Hjalgrim H, Seow A, Rostgaard K, Friborg J: Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer; 2008 Aug 1;123(3):716-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of Hodgkin lymphoma incidence in Singapore.
  • A bimodal age-specific incidence pattern with a relatively high proportion of cases occurring in adolescents and young adults is a hallmark of Hodgkin lymphoma (HL) epidemiology in Western industrialized countries.
  • The young adult incidence peak is believed to reflect the association between HL risk in young adults and an affluent childhood socioeconomic environment.
  • However, the dynamic development of the young adult incidence peak following socioeconomic development implied by this interpretation has scarcely been demonstrated in a single population over time.
  • As hypothesized a HL incidence peak emerged among adolescents and young adults in Singapore.
  • However, the incidence peak remained considerably lower than what can be observed in young adults in the Western World.
  • It remains to be determined to what extent the current lower incidence of HL in young Asian adults should be attributed to birth cohort phenomena, as would be suggested by continued increase in incidence, and to ethnic variation in HL susceptibility between Asian and non-Asian populations, respectively.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Confidence Intervals. Female. Genetic Predisposition to Disease. Humans. Incidence. Infant. Male. Middle Aged. Poisson Distribution. Singapore / epidemiology. Socioeconomic Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470916.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Claude L, Schell M: [Hodgkin's disease: treatment specificities in childhood]. Cancer Radiother; 2009 Oct;13(6-7):527-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's disease: treatment specificities in childhood].
  • [Transliterated title] Maladie de Hodgkin : spécificités de la prise en charge en pédiatrie.
  • Paediatric Hodgkin disease presents some particularities when compared to Hodgkin in adults.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aging / physiology. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. France / epidemiology. Humans. Incidence. Radiotherapy Dosage. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783192.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Gross TG, Termuhlen AM: Pediatric non-Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):167-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually.
  • NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes.
  • This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Curr Oncol Rep. 2007 Nov;9(6):459-65 [17991353.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13 [12571460.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E8 [17134124.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2319-33 [11304786.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6481-8 [16170157.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):399-405 [11699405.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):536-44 [10573576.001]
  • [Cites] Inflamm Bowel Dis. 2007 Aug;13(8):1024-30 [17480018.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • (PMID = 20425462.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Grulich AE, Vajdic CM: The epidemiology of non-Hodgkin lymphoma. Pathology; 2005 Dec;37(6):409-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) includes a group of more than 20 different malignant lymphoproliferative diseases that originate from lymphocytes.
  • These include immune-deficiency-associated central nervous system NHL (Epstein-Barr virus); gastric mucosa-associated lymphoid tissue NHL (Helicobacter pylori); adult T-cell leukemia/lymphoma (human T-lymphotrophic virus type 1) and body cavity-based lymphoma (human herpesvirus 8).
  • Specific autoimmune conditions, including rheumatoid arthritis, systemic lupus erythema, Sjogren's syndrome, psoriasis and coeliac disease are associated with moderately increased risk of NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373224.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 147
  •  go-up   go-down


43. Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):126-31
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin lymphoma.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation.
  • Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of choice for stage IA NLPHL.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Recurrence. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1984 Apr;8(4):253-61 [6369997.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:83-92 [2049324.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):179-85 [17526010.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i54-5 [15888755.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] Am J Clin Oncol. 2007 Dec;30(6):601-6 [18091054.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):434-9 [18086799.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425457.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


44. Oshikawa G, Arai A, Sasaki K, Ichinohasama R, Miura O: [Primary multifocal osseous Hodgkin lymphoma]. Rinsho Ketsueki; 2009 Feb;50(2):92-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary multifocal osseous Hodgkin lymphoma].
  • Core needle biopsy of the sternal tumor was performed and a diagnosis of Hodgkin lymphoma (HL) (mixed cellularity) was made.
  • Neither bone marrow biopsy nor cerebrospinal fluid examination showed infiltration of lymphoma cells.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Positron-Emission Tomography. Remission Induction. Tomography, X-Ray Computed. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265301.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 15
  •  go-up   go-down


45. Alkhalil A, Elziere C, Kelaidi C, Belin C, Salama J: [Intracranial localization revealing Hodgkin's disease]. Rev Neurol (Paris); 2008 Feb;164(2):200-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial localization revealing Hodgkin's disease].
  • [Transliterated title] Lésion intracrânienne révélatrice d'une maladie de Hodgkin.
  • The central nervous system's (CNS) involvement is uncommon in Hodgkin's disease (HD) and usually occurs in patients with relapsing disease many years after the initial diagnosis.
  • We report the case of a 27-year-old woman with seizure and a left cerebrodural mass on the cerebral imaging; secondarily, she developed cervical lymph node swelling; histological examination of the node revealed HD of the nodular sclerosis type.
  • The dural lesion resolved after chemotherapy for HD.
  • [MeSH-major] Brain / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Image Enhancement. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358882.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Miltényi Z, Székely G, Simon Z, Keresztes K, Illés A: [Differences of arteria carotis in patients with Hodgkin's lymphoma]. Magy Onkol; 2005;49(4):343-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differences of arteria carotis in patients with Hodgkin's lymphoma].
  • [Transliterated title] Arteria carotis-eltérések kezelt Hodgkin-lymphomás betegek között.
  • We examined arteria carotis atherosclerosis and stenosis in Hodgkin's lymphoma patients.
  • We examined arteria carotis of 120 Hodgkin's lymphoma patients who have been in complete remission for at least 5 years.
  • Carotis stenosis does not seem to play a role in late mortality in Hodgkin's lymphoma, but if the patient has an increased risk for atherosclerotic changes, then regular examinations are necessary, and other risk factors (smoking, hypertension, diabetes mellitus, hypothyroidism, early menopause) need to be treated.
  • [MeSH-major] Carotid Arteries / pathology. Carotid Stenosis / pathology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518480.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


47. Adamson P, Bray F, Costantini AS, Tao MH, Weiderpass E, Roman E: Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer; 2007 Jan;43(2):391-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe.
  • Lymphoma incidence is reported to be increasing globally.
  • Trends in the registration rates of both non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in Europe are presented.
  • [MeSH-major] Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Europe / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Regression Analysis. Sex Distribution. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134891.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Werbrouck B, Meire V, De Bleecker JL: Multiple neurological syndromes during Hodgkin lymphoma remission. Acta Neurol Belg; 2005 Mar;105(1):48-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple neurological syndromes during Hodgkin lymphoma remission.
  • We report a young patient who developed a stiff man syndrome (SMS) long after remission of Hodgkin lymphoma.
  • This patient is remarkable because he has had several other potentially autoimmune or paraneoplastic neurological syndromes including limbic encephalitis and demyelinating polyneuropathy which also occurred years after remission from Hodgkin disease.
  • [MeSH-major] Hodgkin Disease / complications. Paraneoplastic Syndromes, Nervous System / etiology. Stiff-Person Syndrome / etiology
  • [MeSH-minor] Adult. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861997.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


49. Mitterlechner T, Fiegl M, Mühlböck H, Oberaigner W, Dirnhofer S, Tzankov A: Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol; 2006 Jan;59(1):48-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.
  • AIMS: To analyse the entity specific incidence and disease specific survival (DSS) of non-Hodgkin lymphomas (NHLs) in Tyrol/Austria, 1991-2000.
  • There was a significant increase in diffuse large B cell lymphoma (DLBCL) and decrease in CLL/SLL in men, and a decrease in MM in women.
  • In B-NHL, DSS decreased in the following order: hairy cell leukaemia, marginal zone lymphoma, follicular lymphoma, Burkitt lymphoma, ALL, DLBCL, CLL, MM, and mantle cell lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Austria / epidemiology. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Sex Distribution

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Am J Epidemiol. 1998 Nov 1;148(9):833-41 [9801013.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):361-8 [11319177.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Oncologist. 2001;6(3):247-56 [11423671.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):50-5 [11753078.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] Biomed Pharmacother. 2002 Jul;56(5):223-34 [12199621.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):1071-7 [12199787.001]
  • [Cites] Dtsch Med Wochenschr. 2002 Oct 25;127(43):2253-8 [12397539.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):892 [12461049.001]
  • [Cites] J Mol Cell Cardiol. 2002 Dec;34(12):1595-607 [12505058.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):193 [12610096.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3181-7 [12515730.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):451-8 [12688314.001]
  • [Cites] Can J Gastroenterol. 2003 Jun;17 Suppl B:49B-52B [12845352.001]
  • [Cites] Autoimmun Rev. 2003 May;2(3):119-25 [12848952.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):99-105 [12925963.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1704-6 [14594618.001]
  • [Cites] Br J Haematol. 2004 May;125(3):294-317 [15086411.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1215-21 [15277261.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):227-38 [15322489.001]
  • [Cites] Blood. 1976 Jul;48(1):41-51 [820387.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):755-6 [2210891.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):163-4 [1728608.001]
  • [Cites] Am J Public Health. 1992 Jul;82(7):990-7 [1609918.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5453s-5455s [1394153.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5465s-5467s [1327508.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2386-9 [8162585.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1707-15 [9846961.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):155-63 [10319384.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):627-33 [10492638.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):698-706 [10505027.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Immunology. 2005 Jan;114(1):37-43 [15606793.001]
  • [Cites] Transfus Med Rev. 2000 Jul;14(3):258-68 [10914420.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):12-20 [10561013.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):21-5 [10561014.001]
  • [Cites] Cancer Causes Control. 1999 Dec;10(6):617-25 [10616830.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):713-5 [7917925.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1753-7 [8983286.001]
  • [Cites] Ann Intern Med. 1997 Sep 1;127(5):365-71 [9273827.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Transfusion. 1997 Oct;37(10):1084-92 [9354830.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):49-56 [9486463.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):621-5 [9681531.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1184-91 [9777980.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Haematologica. 2001 Jan;86(1):58-63 [11146572.001]
  • (PMID = 16394280.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860250
  •  go-up   go-down


50. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP: Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant; 2008 Apr;14(4):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
  • Allogeneic stem cell transplantation (SCT) with reduced-intensity conditioning (RIC) has the potential to lead to long-term remissions for patients with lymphoma.
  • However, the role of RIC SCT in the treatment of lymphoma is still unclear.
  • Specifically, the relative benefit of RIC SCT across lymphoma histologies and the prognostic factors in this population are incompletely defined.
  • We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan.
  • Thirty-six patients had Hodgkin disease (HD) and 51 had non-Hodgkin lymphoma (NHL).
  • Three-year overall survival (OS) was 56% for patients with HD, 81% for indolent NHL, 42% for aggressive NHL, and 40% for mantle cell lymphoma.
  • These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2342-50 [8246023.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1291-6 [8648386.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):655-61 [16007106.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):235-44 [16513231.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 [17084369.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4314-21 [11731514.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • (PMID = 18342784.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NHLBI NIH HHS / HL / HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NHLBI NIH HHS / HL / HL070149-05; United States / NHLBI NIH HHS / HL / P01 HL070149-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS43829; NLM/ PMC2364453
  •  go-up   go-down


51. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol; 2009 Jan;144(1):24-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
  • Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15-19 year age group.
  • Hodgkin lymphoma (HL) accounts for the majority (two-thirds) of cases, while the remainder of patients have one of four subtypes of non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL).
  • Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma.
  • This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Humans. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087093.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 115
  •  go-up   go-down


52. Cabrera ME, García H, Lois V, León A, Peña K, Rossle A, Cerda B, Rojas H, Meneses P, Merino C, Aspillaga A, Vittini de C, Oliva J, Hales C, Rosas J, Programa Nacional de Cáncer del Adulto, Ministerio de Salud: [Hodgkin lymphoma in Chile: experience of the national adult cancer program]. Rev Med Chil; 2007 Mar;135(3):341-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
  • [Transliterated title] Linfoma de Hodkin en Chile: experiencia de 15 años del Programa Nacional de Cáncer del Adulto.
  • BACKGROUND: Hodgkin lymphoma is a highly curable disease.
  • AIM: To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile.
  • PATIENTS AND METHODS: Prospective assessment of 682 patients treated in 18 adult cancer centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. National Health Programs
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chi-Square Distribution. Chile. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505580.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Chile
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; ABVD protocol; CMOPP protocol; NOVP protocol
  • [Investigator] Hales C; López H; Zambrano V; Blanchard N; Vacarezza R; Merino C; Toro I; Meneses P; Rojas B; Aspillaga A; Fahrenkrog A; Rossle A; Bancalari G; Fernández A; García C; Schorwer M; Pérez C; Oliva J; Vittini de R C; Yáñez E; Peña A; Rodríguez C; León A; Pilleux L; Calderón S; Salas P; Lesina B; Zapata C; Cardemil B; Zumelzu N; Silva M; Rosas J; González ML; Liberón B; Cerda B; Klivadenko W; Sola A; Cao C; Peña K; Puente L; Bronfman L; Torrens M; Gutiérrez J; Cabrera ME; Undurraga MS; Gray AM; Puga B; Guerra C; Vacarezza R; Etcheverrry R; Ducach G; García H; Riquelme AM; Corvalán H; Lois V; Con I; Muñoz L; Bustos MI; Castro JL; Liendo F; Osorio G; Araos D; Anguita T; Rojas H; Suárez D
  •  go-up   go-down


53. Lin HM, Teitell MA: Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol; 2005 Jan;27(1):28-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy after treatment of pediatric Hodgkin disease.
  • Although treatment of pediatric Hodgkin disease has become highly effective over the past 40 years, a number of patients have developed concerning late effects, such as secondary malignancies.
  • There is also an increased risk of leukemia and non-Hodgkin lymphoma.
  • The information may allow clinicians to better monitor childhood Hodgkin disease survivors and reduce mortality.
  • [MeSH-major] Hodgkin Disease / pathology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Humans. Infant. Infant, Newborn. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654275.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA107300; United States / NCI NIH HHS / CA / CA90571
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


54. Hua MT, Blaise P, De Leval L, Rakic JM: Frosted branch angiitis with undiagnosed Hodgkin lymphoma. Eur J Ophthalmol; 2009 Mar-Apr;19(2):310-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frosted branch angiitis with undiagnosed Hodgkin lymphoma.
  • PURPOSE: To report the case of a patient with bilateral frosted branch angiitis and undiagnosed Hodgkin lymphoma.
  • A supraclavicular lymph node biopsy led to the diagnosis of nodular sclerosis Hodgkin lymphoma.
  • CONCLUSIONS: The occurrence of frosted branch angiitis in combination with classical Hodgkin lymphoma, although possibly coincidental, raises the possibility of a paraneoplastic syndrome.
  • Thus, we suggest that, for patients with frosted branch angiitis, Hodgkin lymphoma should be considered in the diagnostic workup.
  • [MeSH-major] Hodgkin Disease / diagnosis. Retinal Vasculitis / diagnosis
  • [MeSH-minor] Administration, Oral. Biopsy. Fluorescein Angiography. Glucocorticoids / therapeutic use. Humans. Infusions, Intravenous. Lymph Nodes / pathology. Male. Methylprednisolone / therapeutic use. Visual Acuity. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253256.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


55. Feltl D, Markova J, Mocikova H, Dedeckova K, Kozak T: Prognostic impact of bone involvement in Hodgkin lymphoma. Neoplasma; 2008;55(2):96-100
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of bone involvement in Hodgkin lymphoma.
  • The purpose of the study is to determine incidence and prognostic impact of osseous Hodgkin lymphoma (HL).
  • All patients were treated according to protocols of the German Hodgkin Study Group (GHSG).
  • We recorded 14 cases of osseous HL (7 %), always with concurrent nodal disease.
  • [MeSH-major] Bone Neoplasms / mortality. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18237246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


56. Setty BA, Termuhlen AM: Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep; 2010 Jul;5(3):163-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pediatric non-hodgkin lymphoma.
  • Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults.
  • Understanding of these rare types of NHL comes from small pediatric case series or the adult literature.
  • Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Child. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1197-200 [17107389.001]
  • [Cites] J Dermatol. 2009 Jul;36(7):392-402 [19583687.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:349-58 [19074109.001]
  • [Cites] Leuk Lymphoma. 2006 May;47(5):865-9 [16753871.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):158-62 [17011988.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):566-70 [19058208.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1855-64 [11251018.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):212-5 [19856396.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Mar;107(3):393-7 [19121958.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Eur J Haematol. 2009 Sep;83(3):165-74 [19548917.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]
  • [Cites] Semin Diagn Pathol. 1995 Nov;12(4):314-24 [8578026.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):250-2 [15072617.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):29-33 [18300314.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33 Suppl 2:1-5 [16972944.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1109-11 [11025614.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Am J Hematol. 2004 Apr;75(4):195-9 [15054808.001]
  • [Cites] Blood. 2006 Jul 1;108(1):311-8 [16543468.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1258-64 [12495899.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1600-9 [18567836.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Arch Dermatol. 2007 Dec;143(12):1520-6 [18087001.001]
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):315-20 [15101717.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 20490722.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


57. Herbertson RA, Evans LS, Hutchinson J, Horsman J, Hancock BW: Poor outcome in adolescents with high-risk Hodgkin lymphoma. Int J Oncol; 2008 Jul;33(1):145-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome in adolescents with high-risk Hodgkin lymphoma.
  • This retrospective study looks at the differences between adolescents (15-19 years) and young adults (20-25 years), diagnosed with Hodgkin lymphoma and treated at the same adult institution.
  • Outcome according to risk category was evaluated, and although there were no significant differences in the whole cohort, or low and intermediate-risk categories, high-risk adolescent patients had a significantly worse outcome compared to that of young adults.
  • In these high-risk patients, 5-year event free survival was 43.6% in adolescents compared to 58.7% in young adults (log-rank survival p=0.03), and the 5-year overall survival in adolescents was 66.7% compared to 84.4% in the young adults (p=0.04).
  • The difference could not be explained in terms of differences in histological subtype (p=0.5), proportion of patients with bulky (p=0.6) or extranodal disease (p=0.6), initial treatment received (chemotherapy alone compared to combination therapy, p=0.2), or proportion proceeding to high-dose treatment after initial treatment failure (p=0.6).
  • A significantly greater proportion of high-risk adolescents had primary progressive disease (PPD) [eight high-risk adolescents (33.3%) compared to two high-risk young adults (7.7%), p=0.02].
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Humans. Retrospective Studies. Risk

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575760.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


58. Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF: Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer; 2005 Sep 10;116(4):646-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma.
  • Somatic inactivation of NFKBIA, the gene encoding IkappaBalpha, is a frequent occurrence in the malignant Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL).
  • [MeSH-major] Genetic Predisposition to Disease. Germ-Line Mutation. Hodgkin Disease / genetics. I-kappa B Proteins / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. DNA Mutational Analysis. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Molecular Sequence Data. Pedigree. Polymorphism, Genetic. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15858823.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins
  •  go-up   go-down


59. Martín-Subero JI, Klapper W, Sotnikova A, Callet-Bauchu E, Harder L, Bastard C, Schmitz R, Grohmann S, Höppner J, Riemke J, Barth TF, Berger F, Bernd HW, Claviez A, Gesk S, Frank GA, Kaplanskaya IB, Möller P, Parwaresch RM, Rüdiger T, Stein H, Küppers R, Hansmann ML, Siebert R, Deutsche Krebshilfe Network Project Molecular Mechanisms in Malignant Lymphomas: Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res; 2006 Nov 1;66(21):10332-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
  • However, despite the predominant B-cell origin of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL), the presence of chromosomal translocations in IG loci has not yet been systematically explored.
  • [MeSH-major] Chromosome Breakage. Genes, Immunoglobulin Heavy Chain. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Caspases / genetics. DNA-Binding Proteins / genetics. Female. Genes, myc. Humans. Immunoglobulin Class Switching. Immunoglobulin Constant Regions / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079453.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Constant Regions; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


60. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


61. Melbye M, Smedby KE, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, Schöllkopf C, Sundström C, Chang ET, Koskela P, Adami HO, Hjalgrim H: Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst; 2007 Jan 17;99(2):158-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy and risk of non-Hodgkin lymphoma.
  • BACKGROUND: A possible connection between allergy and cancer has been suspected, but allergy-related conditions or atopy have been inconsistently associated with reduced risks of non-Hodgkin lymphoma.
  • METHODS: We carried out a population-based study of 3055 case patients with non-Hodgkin lymphoma and 3187 control subjects in Denmark and Sweden, including questionnaire information on allergy and blood specimens, and a nested case-control study within a prospective cohort of more than 400,000 Finnish women.
  • In the second study, serum specimens from the 198 case patients who developed non-Hodgkin lymphoma within a median of 8.9 years after the blood was drawn were matched with serum specimens from 594 control subjects.
  • Dissemination of disease was classified by the Ann Arbor system.
  • RESULTS: In the first study, ever having hay fever, but not other allergic conditions, was associated with a reduced risk of non-Hodgkin lymphoma.
  • In particular, subjects with specific IgE reactivity in serum had a 32% (95% CI = 20% to 42%) lower risk of overall non-Hodgkin lymphoma than those without such reactivity.
  • However, among case patients, dissemination of the disease was strongly inversely associated with specific IgE reactivity.
  • In the second (i.e., prospective) study, no association was found between non-Hodgkin lymphoma and specific IgE reactivity, except possibly immediately before a diagnosis of non-Hodgkin lymphoma (> or = 10 years before diagnosis, OR = 1.00, 95% CI = 0.48 to 2.09; 5-9 years before, OR = 0.95, 95% CI = 0.50 to 1.84; 1-4 years before, OR = 0.33, 95% CI = 0.11 to 1.02; and < 1 year before, OR = 0.27, 95% CI = 0.03 to 2.31).
  • CONCLUSION: Allergy may not be causally associated with the risk of non-Hodgkin lymphoma.
  • The inverse association observed in some case-control studies may arise because non-Hodgkin lymphoma suppresses the immunologic response to allergens.
  • [MeSH-major] Hypersensitivity, Immediate / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Denmark / epidemiology. Female. Finland / epidemiology. Humans. Immunoglobulin E / immunology. Logistic Models. Male. Middle Aged. Odds Ratio. Prospective Studies. Retrospective Studies. Rhinitis, Allergic, Perennial / complications. Risk Assessment. Risk Factors. Selection Bias. Surveys and Questionnaires. Sweden / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Sep 19;99(18):1417 [17848674.001]
  • (PMID = 17227999.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R03 CA 101496-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


62. Hodgson DC, Hudson MM, Constine LS: Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol; 2007 Jul;17(3):230-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity.
  • Historically, both adult and childhood Hodgkin lymphoma (HL) were treated with full-dose (35-45 Gy) extended-field radiation therapy (RT).
  • Although this treatment was the first to produce reliable disease control, the resulting late toxicity led pediatric oncologists to pioneer the use of combined chemotherapy and low-dose (15-25 Gy) involved-field RT for all stages of HL.
  • Currently, standard treatment of childhood HL is risk adapted; those with favorable risk disease typically receive 2 to 4 cycles of multi-agent chemotherapy with low-dose IFRT, whereas those with higher-risk disease receive more intensive chemotherapy before IFRT.
  • In contrast to adult HL, IFRT remains an important component of the treatment of advanced-stage HL in pediatric patients.
  • The challenge is to refine therapy in a rare disease in which long-time intervals are necessary to observe an adequate number of events (treatment failure or late effects) to answer judicious questions.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Humans. Neoadjuvant Therapy. Neoplasm Staging. Patient Care Planning. Prognosis. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591570.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


63. Roper K, McDermott K, Cooley ME, Daley K, Fawcett J: Health-related quality of life in adults with Hodgkin's disease: the state of the science. Cancer Nurs; 2009 Nov-Dec;32(6):E1-17; quiz E18-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in adults with Hodgkin's disease: the state of the science.
  • Hodgkin's disease (HD) affects younger and older adults and can disrupt developmental tasks and cause multiple medical sequelae.
  • This article is an integrative review of empirical studies of HRQOL in HD survivors.
  • Commonly reported physical consequences of HD include fatigue, anticipatory nausea and vomiting, and cognitive problems that lasted several years after treatment completion, as well as long-term life-threatening adverse effects including secondary cancers and cardiovascular and respiratory complications.
  • Development of appropriate theory-guided interventions to improve the HRQOL for HD survivors can be achieved through more rigorous study designs and standardization of HRQOL measurements.
  • [MeSH-major] Education, Nursing, Graduate / standards. Hodgkin Disease / psychology. Oncology Nursing / education. Quality of Life / psychology
  • [MeSH-minor] Adaptation, Psychological. Adult. Humans. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816166.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U56 CA11863502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


64. Chera BS, Olivier K, Morris CG, Lynch JW, Mendenhall NP: Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida. Am J Clin Oncol; 2007 Dec;30(6):601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
  • OBJECTIVE: To examine the clinical presentation and treatment outcomes of lymphocyte-predominant Hodgkin disease (LPHD) at the University of Florida over a 37-year period.
  • RESULTS: Ninety-six percent of patients presented with stage I/II disease.
  • None had mediastinal disease, 4 (12%) had bulky disease (>6 cm in maximum tumor dimension), and only 1 (3%) had B symptoms.
  • No patients died with Hodgkin disease, but 1 patient's death was attributed to treatment-related late sequelae.
  • CONCLUSION: LPHD patients typically present at an early stage without B symptoms, mediastinal, or bulky disease.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Florida. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091054.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood; 2008 Mar 1;111(5):2825-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in classic Hodgkin lymphoma.
  • We analyzed miRNA expression in classic Hodgkin lymphoma (cHL) and the influence of Epstein-Barr virus (EBV) infection on the miRNA expression profiles.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Herpesvirus 4, Human / physiology. Humans. In Situ Hybridization. Lymph Nodes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


66. Bartlett NL: Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program; 2005;:245-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
  • Autologous stem cell transplant remains the standard of care for relapsed Hodgkin lymphoma (HL).
  • For patients with chemo-refractory disease at relapse and those failing autologous transplant, the long-term prognosis remains poor.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304388.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


67. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC: Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol; 2010 Dec;28(4):168-79
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preservation after chemotherapy for Hodgkin lymphoma.
  • Treatment for Hodgkin lymphoma can negatively affect fertility.
  • This review summarizes data on fertility after chemotherapy in adult patients.
  • For females with a partner, IVF followed by embryo cryopreservation is a widely available method, but this necessitates postponement of lymphoma therapy for at least a month.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Azoospermia / chemically induced. Cryopreservation / methods. Female. Humans. Male. Ovarian Diseases / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [CommentIn] Hematol Oncol. 2011 Mar;29(1):52; author reply 53 [20535782.001]
  • (PMID = 20232475.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


68. Willett EV, Roman E: Obesity and the risk of Hodgkin lymphoma (United Kingdom). Cancer Causes Control; 2006 Oct;17(8):1103-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and the risk of Hodgkin lymphoma (United Kingdom).
  • OBJECTIVE: The aim of the study was to investigate the relationship between Hodgkin lymphoma (HL) and obesity.
  • METHODS: A population-based case-control study recruited incident cases of lymphoma in England during 1998-2003.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Risk Factors


69. Mearin ML, Catassi C, Brousse N, Brand R, Collin P, Fabiani E, Schweizer JJ, Abuzakouk M, Szajewska H, Hallert C, Farré Masip C, Holmes GK, Biomed Study Group on Coeliac Disease and Non-Hodgkin Lymphoma: European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol; 2006 Feb;18(2):187-94
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European multi-centre study on coeliac disease and non-Hodgkin lymphoma.
  • INTRODUCTION: Coeliac disease (CD) is associated with an increased risk of non-Hodgkin lymphoma (NHL), but there is little information about whether this is true for clinically silent CD.
  • [MeSH-major] Celiac Disease / complications. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Algorithms. Epidemiologic Methods. Europe / epidemiology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gastroenterol Hepatol. 2006 Feb;18(2):131-2 [16394793.001]
  • (PMID = 16394801.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


70. Caillard S, Agodoa LY, Bohen EM, Abbott KC: Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation; 2006 Mar 27;81(6):888-95
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis.
  • BACKGROUND: Hodgkin disease and myeloma were recently included in the classification of posttransplant lymphoproliferative disorder (PTLD).
  • METHODS: The incidence, characteristics, risk, and prognostic factors of myeloma, Hodgkin disease, and lymphoid leukemia using the United States Renal Data System from 1991 to 2000 among 66,159 Medicare patients were analyzed.
  • RESULTS: In all, 1,169 recipients developed a lymphoid disease: 823 (1.2%) non-Hodgkin's lymphomas (NHL), 160 (0.24%) myelomas, 60 (0.1%) Hodgkin lymphomas, and 126 (0.2%) lymphoid leukemias.
  • Induction therapy was associated with a greater risk of myeloma and leukemia, but not Hodgkin disease.
  • Azathioprine was associated with a lower risk of myeloma, and tacrolimus with a lower risk of Hodgkin disease.
  • According to the type of malignancy, ten-year survival rates were significantly different: 42, 26, 55 and 39% respectively for NHL, myeloma, Hodgkin disease, and leukemia.
  • [MeSH-major] Hodgkin Disease / etiology. Kidney Transplantation / adverse effects. Leukemia, Lymphoid / etiology. Multiple Myeloma / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival Rate


71. Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW, EUROCARE Working Group: Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer; 2006 Jul 15;107(2):352-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups.
  • BACKGROUND: The survival of patients with Hodgkin disease (HD) varies markedly across Europe and generally is shorter than the survival of patients in the U.S.
  • To investigate these differences, the authors compared population-based HD survival in relation to morphologic type among populations in Europe and the U.S.
  • CONCLUSIONS: The current results provide population-based evidence that morphology strongly influences the prognosis of patients with HD.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Europe. Female. Humans. Male. Middle Aged. Registries. SEER Program. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770772.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 11700
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, FHDH ANRS CO4 ANRS CO141: Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr; 2009 Feb 1;50(2):206-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
  • Here we compared the risks of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in IL-2-treated and IL-2-untreated HIV-infected patients.
  • CONCLUSIONS: In this large observational study, IL-2 therapy did not increase the risk of lymphoma, either NHL or HL, in HIV-infected patients.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / epidemiology. Interleukin-1 / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Female. France. Hospitals. Humans. Incidence. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131886.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong M; Lang JM; Lascaux A; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard J; Pavie J; Pialoux G; Pilorgé F; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard J; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Abgrall S; Grabar S; Guiguet M; Lanoy E; Lièvre L; Mary-Krause M; Potard V; Selinger-Leneman H; Fichou J; Bouvet E; Crickx B; Ecobichon J; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Salmon D; Sicard D; Auperin I; Gilquin J; Roudière L; Viard J; Boué F; Fior R; Delfraissy J; Goujard C; Jung C; Lesprit P; Desplanque N; Meynard JL; Meyohas M; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel J; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine J; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont J; Moreau J; Gastaut J; Retornaz F; Soubeyrand J; Allegre T; Blanc P; Galinier A; Ruiz J; Lepeu G; Granet-Brunello P; Esterni J; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang J; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand M; Yazdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M; Lévy Y; Aboulker J; Bursachi P; Delfraissy J; Saïdi Y; Lascaux A; Saïdi S; Commoy M; Chêne G; Viard JP; Molina J; Tubiana R; Lascaux AS; Berdah M; Jung C; Molina J; Lafaurie M; Schnell-Niedbalski L; Oksenhendler E; Gérard L; Delfraissy J; Goujard C; Chaix F; Rannou MT; Tegna L; Tisne-Dessus D; Jeanblanc F; Beck-Wirth G; Benomar M; Verdon R; Bazin C; Goubin P; Girard P; Boudraa C; Sebire M; Viard J; Maignan A; Tubiana R; Katlama C; Curjol A; Fabre G; Trepo C; Brochier C; Thoirain V; Bloch M; Mortier E; Dupon M; Raymond I; Ragnaud JM; Raymond I; Sellier P; Magnier JD; Simon A; Iguerstira M; Gastaut J; Dalmas AM; Aboulker J; Guéguen S; Circosta S; Mourlhou P; Saouzanet-Harel M; Izard S; Saïdi Y
  •  go-up   go-down


73. Chan I, McGrath JA, Kivirikko S: Rapp-Hodgkin syndrome and the tail of p63. Clin Exp Dermatol; 2005 Mar;30(2):183-6
Genetic Alliance. consumer health - Rapp-Hodgkin syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapp-Hodgkin syndrome and the tail of p63.
  • We report the clinical and molecular abnormalities in a 19-year-old woman with Rapp-Hodgkin ectodermal dysplasia syndrome.
  • The expanding p63 mutation database demonstrates that there is overlap between Rapp-Hodgkin syndrome and several other ectodermal dysplasia syndromes, notably Hay-Wells syndrome, and that characterization of the functional consequences of these p63 gene mutations at a molecular and cellular level is likely to provide further insight into the clinical spectrum of these developmental malformation syndromes.
  • [MeSH-minor] Adult. Base Sequence. Facial Bones / abnormalities. Facies. Female. Hair / abnormalities. Humans. Mutation. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725251.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L: Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol; 2006 Sep;24(3):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.
  • This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL).
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiography. Positron-Emission Tomography
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18 / administration & dosage. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymph Nodes / radiography. Male. Middle Aged. Radiopharmaceuticals / administration & dosage. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 16729353.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Broderick P, Cunningham D, Vijayakrishnan J, Cooke R, Ashworth A, Swerdlow A, Houlston R: IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol; 2010 Feb;148(3):413-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.
  • The reciprocal familial risk between chronic lymphocytic leukaemia (CLL) and Hodgkin lymphoma (HL) suggests genetic variants with pleiotropic effects may influence the risk of both CLL and HL.
  • [MeSH-major] Hodgkin Disease / genetics. Interferon Regulatory Factors / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Assessment / methods. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804451.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / interferon regulatory factor-4
  •  go-up   go-down


76. Bloom JR, Stewart SL, Hancock SL: Breast cancer screening in women surviving Hodgkin disease. Am J Clin Oncol; 2006 Jun;29(3):258-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer screening in women surviving Hodgkin disease.
  • OBJECTIVE: To inform female Hodgkin disease (HD) survivors, younger than 35 at diagnosis, of their increased risk for breast cancer and encourage them to seek breast cancer screening.
  • Women treated at Stanford University who received thoracic irradiation before age 35, alive and HD-free at last contact, were referred to the project (n = 471).
  • [MeSH-major] Breast Neoplasms / radiography. Counseling. Hodgkin Disease. Patient Education as Topic
  • [MeSH-minor] Adult. Age of Onset. Female. Health Behavior. Humans. Mammography. Neoplasms, Radiation-Induced / radiography. Risk Factors. Survivors. Telephone

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755179.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Simon Z, Ress Z, Toldi J, Trauninger A, Miltényi Z, Illés A: Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility? Int J Hematol; 2009 May;89(4):523-8
MedlinePlus Health Information. consumer health - Myasthenia Gravis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility?
  • With Hodgkin lymphoma (HL), other (autoimmune) diseases may occasionally occur or associate, whereas as a late treatment-complication, second tumour may develop.
  • In 2000 Graves's disease, in 2001 myasthenia gravis was diagnosed, which showed resistance for immunosuppressant drugs, thus plasmapheresis, intravenous immunoglobulin treatments were applied.
  • The disease showed progression despite the chemotherapy applied and the patient died in 2007 due to respiratory failure.
  • Association of Hodgkin lymphoma, and two antibody-mediated autoimmune diseases, Graves' disease and myasthenia gravis, is rare and has not yet been reported in the literature.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Graves Disease / complications. Hodgkin Disease / complications. Myasthenia Gravis / complications. Neurofibrosarcoma / radiotherapy
  • [MeSH-minor] Adult. Autopsy. Fatal Outcome. Female. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed


78. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A: Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma; 2009 Nov;50(11):1803-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
  • The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease.
  • After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aspergillosis / chemically induced. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Pericarditis / chemically induced. Peripheral Blood Stem Cell Transplantation. Pneumonia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Recurrence. Retrospective Studies. Shock, Septic / chemically induced. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Nov;50(11):1733-4 [19883301.001]
  • (PMID = 19860621.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


79. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood; 2006 Dec 1;108(12):3786-91
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.
  • In persons with HIV/AIDS (PWHAs), Hodgkin lymphoma (HL) risk is increased.


80. Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA, McDuffie HH: Ethnicity and incidence of Hodgkin lymphoma in Canadian population. BMC Cancer; 2009;9:141
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and incidence of Hodgkin lymphoma in Canadian population.
  • BACKGROUND: Research has shown that ethnicity is a significant predictor of Hodgkin lymphoma (HL).
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / ethnology
  • [MeSH-minor] Adult. Aged. Canada / epidemiology. Case-Control Studies. Environmental Exposure. Ethnic Groups. Female. Humans. Incidence. Male. Medical History Taking. Middle Aged. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Environ Med. 2005 Aug;47(8):806-16 [16093930.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1441-7 [15941953.001]
  • [Cites] BMC Public Health. 2008;8:152 [18462495.001]
  • [Cites] BMC Cancer. 2009;9:70 [19250521.001]
  • [Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Occup Environ Med. 2003 Oct;60(10):798-801 [14504372.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):572-9 [15226778.001]
  • [Cites] J Lancet. 1966 Jan;86(1):5-11 [5900921.001]
  • [Cites] Br J Cancer. 1966 Sep;20(3):434-7 [5922249.001]
  • [Cites] Scott Med J. 1969 Feb;14(2):51-4 [5812963.001]
  • [Cites] Lancet. 1973 Apr 21;1(7808):884-5 [4123430.001]
  • [Cites] Nature. 1974 Oct 4;251(5474):441-2 [4421071.001]
  • [Cites] Cancer Res. 1980 Jan;40(1):1-12 [7349888.001]
  • [Cites] Br J Cancer. 1981 Feb;43(2):169-76 [7470379.001]
  • [Cites] Br J Cancer. 1983 Aug;48(2):217-25 [6882662.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):66-74 [4014202.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):235-9 [3456062.001]
  • [Cites] JAMA. 1986 Sep 5;256(9):1141-7 [3801091.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1986;41:1-407 [3473020.001]
  • [Cites] Br J Cancer. 1987 Oct;56(4):505-8 [3689667.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):19-24 [3342183.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Scand J Work Environ Health. 1988 Aug;14(4):224-30 [3175554.001]
  • [Cites] Clin Invest Med. 1990 Dec;13(6):333-8 [2078912.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):543-8 [1654982.001]
  • [Cites] Can J Public Health. 1992 Jan-Feb;83(1):31-3 [1571879.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1991;53:5-586 [1688189.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):602-6 [8319194.001]
  • [Cites] BMJ. 1994 Jul 30;309(6950):327-30 [8086873.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):461-2 [7824019.001]
  • [Cites] Cancer Causes Control. 1996 May;7(3):312-21 [8734824.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Histopathology. 1997 Mar;30(3):227-33 [9088951.001]
  • [Cites] Am J Public Health. 1998 Sep;88(9):1303-7 [9736867.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1282-8 [18323551.001]
  • (PMID = 19432977.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2690601
  •  go-up   go-down


81. Scotti SD, Laudadio J: Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET. J Radiol Case Rep; 2009;3(8):18-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.
  • Testicular relapse of leukemia and lymphoma is a well-recognized phenomenon, with testicular relapse of lymphoma being more common in the adult population and leukemia relapse being more common in the pediatric population.
  • With the advent of F-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the evaluation of lymphoma it is possible to evaluate testicular uptake of FDG and to detect primary testicular lymphoma or testicular relapse on the FDG-PET examination.
  • Testicular relapse of non-Hodgkin lymphoma (NHL) detected on FDG-PET has been reported previously.
  • Elevated activity or lateralizing activity should be viewed with suspicion, with etiologies including primary testicular tumor, primary or secondary testicular lymphoma and metastatic disease with other etiologies less likely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vivo. 1991 May-Jun;5(3):297-9 [1893083.001]
  • [Cites] Lancet Oncol. 2002 Jun;3(6):357-63 [12107023.001]
  • [Cites] Cancer. 1969 Jun;23(6):1290-5 [5818886.001]
  • (PMID = 22470678.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303329
  • [Keywords] NOTNLM ; Non-Hodgkin’s Lymphoma / PET / PET/CT / testicular lymphoma
  •  go-up   go-down


82. El-Zein R, Monroy CM, Etzel CJ, Cortes AC, Xing Y, Collier AL, Strom SS: Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer; 2009 Apr 15;115(8):1651-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk.
  • BACKGROUND: Although the pathogenesis of Hodgkin disease (HD) remains unknown, the results of epidemiologic studies suggest that heritable factors are important in terms of susceptibility.
  • However, to the authors' knowledge, few studies to date have investigated the role of such polymorphisms as risk factors for development of HD.
  • METHODS: The authors evaluated the relation between polymorphisms in 3 nucleotide excision repair pathway genes (XPD [Lys751Gln], XPC [Lys939Gln], and XPG [Asp1104His]), the base excision repair XRCC1 (Arg399Gln), and double-strand break repair XRCC3 (Thr241Met) in a population of 200 HD cases and 220 matched controls.
  • RESULTS: A positive association was found for XRCC1 gene polymorphism Arg399Gln (OR, 1.77; 95% confidence interval [95% CI], 1.16-2.71) and risk of HD.
  • The combined analysis demonstrated that XRCC1/XRCC3 and XRCC1/XPC polymorphisms were associated with a significant increase in HD risk.
  • Similarly, XRCC1 Arg/Gln together with XPC Lys/Lys was found to significantly increase the risk of HD (OR, 2.14; 95% CI, 1.09-4.23).
  • CONCLUSIONS: These data suggest that genetic polymorphisms in DNA repair genes may modify the risk of HD, especially when interactions between the pathways are considered.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1996 Dec 2;15(23):6662-70 [8978692.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):687-92 [9298575.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2557-61 [10363972.001]
  • [Cites] Nat Struct Biol. 1999 Sep;6(9):884-93 [10467102.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93 [15533908.001]
  • [Cites] Cancer Lett. 2004 Dec 28;216(2):157-64 [15533591.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2556-63 [11909950.001]
  • [Cites] Mutat Res. 2002 May 22;502(1-2):61-8 [11996973.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1142-3 [12376526.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1677-81 [12869423.001]
  • [Cites] Cancer Lett. 2004 Mar 31;206(1):51-8 [15019159.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1463-72 [15368334.001]
  • [Cites] Int J Hyg Environ Health. 2004 Sep;207(4):301-13 [15471094.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):589-93 [8514450.001]
  • [Cites] Cancer. 1993 Aug 1;72(3 Suppl):991-5 [8334675.001]
  • [Cites] Int J Cancer. 1995 Feb 20;64(1):14-7 [7665242.001]
  • [Cites] Clin Chem. 1995 Dec;41(12 Pt 2):1848-53 [7497644.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3975-9 [8752166.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4103-7 [8797573.001]
  • [Cites] Med Hypotheses. 1996 Sep;47(3):199-213 [8898321.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 15;24(22):4387-94 [8948628.001]
  • [Cites] Hum Genet. 2006 Feb;118(6):669-79 [16323010.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):258-65 [16492913.001]
  • [Cites] Am J Hum Genet. 2006 Dec;79(6):1002-16 [17186459.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1395-404 [17283177.001]
  • [Cites] Cancer Sci. 2007 May;98(5):716-20 [17355263.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2687-95 [17290394.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):715-26 [17470739.001]
  • [Cites] Mutat Res. 2007 Jul 28;631(2):101-10 [17531525.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2453-6 [17695538.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1180-5 [17666372.001]
  • [Cites] BMC Cancer. 2007;7:162 [17705814.001]
  • [Cites] Hum Mol Genet. 2007 Dec 15;16(24):3117-27 [17901044.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):97-100 [18315909.001]
  • [Cites] Hum Genet. 2006 Jul;119(6):659-68 [16738949.001]
  • [Cites] J Theor Biol. 2006 Jul 21;241(2):252-61 [16457852.001]
  • [Cites] Am J Epidemiol. 2006 Aug 15;164(4):297-302 [16707649.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1828-34 [16543247.001]
  • [Cites] Mol Carcinog. 2006 Sep;45(9):715-9 [16652373.001]
  • [Cites] Mutat Res. 2006 Aug 30;600(1-2):184-92 [16824555.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3161-7 [16857995.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1766(2):168-83 [17141416.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):67-74 [15837542.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5389-95 [15964796.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1536-41 [15878910.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6593-600 [16425350.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):874-97 [10841823.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):63-71 [10974407.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Biochemistry. 2001 May 22;40(20):5906-13 [11352725.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1437-45 [11532866.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):121-7 [11668486.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):22-33 [11900249.001]
  • (PMID = 19280628.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA55769; United States / NCI NIH HHS / CA / CA98549; United States / NCI NIH HHS / CA / R01 CA123208; United States / NCI NIH HHS / CA / R01 CA098549; United States / NCI NIH HHS / CA / R01 CA123208-03; United States / NCI NIH HHS / CA / R01 CA055769; None / None / / R01 CA123208-03; United States / NIEHS NIH HHS / ES / P30 ES007784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA excision repair protein ERCC-5; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3; 156533-34-5 / XPC protein, human; EC 3.1.- / Endonucleases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  • [Other-IDs] NLM/ NIHMS129912; NLM/ PMC2854485
  •  go-up   go-down


83. Kyrmizakis DE, Hajiioannou JK, Koutsopoulos AV, Papadaki E, Papadakis D, Bizakis J, Velegrakis G: Primary nasal non-Hodgkin lymphomas presented initially as benign disease. Am J Otolaryngol; 2006 May-Jun;27(3):217-20
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasal non-Hodgkin lymphomas presented initially as benign disease.
  • BACKGROUND: Primary non-Hodgkin lymphomas (NHLs) of the sinonasal tract comprise a rare entity that constitutes 1.5% of all NHLs and 2.2% of extranodal lymphomas in the whites.
  • CONCLUSION: It is important to underline that atypical or persistent symptoms of rhinosinusitis may represent the initial expression of a more serious condition such as deep fungal infection, vasculitis, lymphoma, or other malignancy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Endoscopy. Fatal Outcome. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647990.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Aguilera NS, Chen J, Bijwaard KE, Director-Myska AE, Barekman CL, Millward C, Lichy J, Abbondanzo SL: Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens. Arch Pathol Lab Med; 2006 Dec;130(12):1772-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens.
  • CONTEXT: Reed-Sternberg cells in classic Hodgkin lymphoma are enigmatic and difficult to study because they are so sparse.
  • Rarely, Reed-Sternberg cells in classic Hodgkin lymphoma express T-cell antigens, suggesting a possible T-cell origin.
  • OBJECTIVE: To determine whether there is a difference in genotype between classic Hodgkin lymphoma and classic Hodgkin lymphoma expressing T-cell antigens and to document T-cell clonality.
  • DESIGN: We studied 4 cases of Hodgkin lymphoma with a characteristic phenotype and immunoreactivity for CD2 and CD3.
  • Comparative genomic hybridization analysis revealed significant overlap in genomic alteration in Hodgkin lymphoma cases regardless of genotype or phenotype and several regions of imbalance specific to CD3+ Hodgkin lymphoma cases.
  • All patients are alive with no evidence of disease from 10 to 44 months.
  • CONCLUSIONS: Our findings suggest that a T-cell phenotype classic Hodgkin lymphoma can be supported by genotypic studies and that there may be cytogenetic differences between classic Hodgkin lymphoma and Hodgkin lymphoma expressing T-cell antigens.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Nucleic Acid Hybridization / methods. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Clone Cells. Female. Genotype. Humans. Immunohistochemistry. Lasers. Lymph Nodes / pathology. Microdissection

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149949.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Krishnamurthy S, Hassan A, Frater JL, Paessler ME, Kreisel FH: Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease. Int J Surg Pathol; 2010 Aug;18(4):278-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
  • Because of its rarity, pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) are not well understood, and it is unclear whether its biological behavior is more closely related to classical Hodgkin disease or to monomorphic B-cell PTLD.
  • Although all patients diagnosed with monomorphic B-cell PTLD show no evidence of disease following treatment, half of the patients with HL-like PTLD relapsed or died, indicating a more aggressive clinical behavior.
  • [MeSH-major] B-Lymphocytes / pathology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Immunosuppression. Immunosuppressive Agents / adverse effects. Male. Middle Aged. Postoperative Complications. RNA-Binding Proteins / metabolism. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Ribosomal Proteins / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Surg Pathol. 2010 Oct;18(5):444
  • (PMID = 19578050.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunosuppressive Agents; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


86. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol; 2006 Jan;17(1):117-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?
  • BACKGROUND: The clinical impact of fused PET/CT data on staging and patient management of Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) was assessed.
  • PATIENTS AND METHODS: A total of 103 consecutive patients with newly diagnosed NHL (n = 68) and HD (n = 35) were assessed retrospectively.
  • Disease was upstaged by PET/CT in 31% (mostly in stages I and II) and downstaged in only 1% of patients.
  • For HD patients, disease was upstaged by PET/CT in 32% and downstaged by PET/CT in 15% (P = NS).
  • CONCLUSIONS: The addition of PET/CT to CT changed the management decisions in approximately a quarter of NHL and a third of HD patients, mostly in early disease stages.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192294.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


87. Saitoh T, Matsushima T, Yamane A, Sakuraya M, Irisawa H, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H: Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes. Acta Haematol; 2007;117(4):238-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes.
  • Immunologic abnormalities have been described in patients with Hodgkin lymphoma, including autoimmune hemolytic anemia and immune thrombocytopenic purpura.
  • The concurrent diagnoses of Hodgkin lymphoma and acquired aplastic anemia, however, is extremely rare.
  • We report a 56-year-old Japanese female patient with severe aplastic anemia and increased large granular lymphocytes prior to the recurrence of Hodgkin lymphoma.
  • After being in remission for 10 years from Hodgkin lymphoma, she developed progressive pancytopenia.
  • No lymphadenopathy was observed that would suggest a relapse of Hodgkin lymphoma.
  • Autopsy revealed the recurrence of Hodgkin lymphoma, nodular sclerosis in the lymph nodes and markedly hypocellular bone marrow.
  • Although autoimmune disorders are described in Hodgkin lymphoma, our case shows a rare instance of a patient who had aplastic anemia as the first manifestation of a relapse of Hodgkin lymphoma.
  • [MeSH-major] Anemia, Aplastic / complications. Hodgkin Disease / complications. Lymphocytes / cytology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Transfusion. Female. Humans. Magnetic Resonance Imaging. Middle Aged


88. Engels EA, Rollison DE, Hartge P, Baris D, Cerhan JR, Severson RK, Cozen W, Davis S, Biggar RJ, Goedert JJ, Viscidi RP: Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer; 2005 Dec 20;117(6):1013-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma.
  • Because JCV can infect lymphocytes and cause chromosomal damage, it is a plausible candidate to cause non-Hodgkin lymphoma (NHL).
  • Because no deficit of BKV antibody was seen in NHL cases, and because antibody levels did not change materially with chemotherapy, we suggest that the lower levels of JCV antibody observed in NHL patients may not be due entirely to a disease or treatment effect.
  • [MeSH-major] Antibodies, Viral / blood. BK Virus / immunology. JC Virus / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. DNA, Viral / urine. Female. HIV Infections / virology. Homosexuality. Humans. Immunoglobulin G / blood. Male. Middle Aged. National Institutes of Health (U.S.). Polymerase Chain Reaction. Registries. SEER Program. United States. Virus Replication. Virus Shedding

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986438.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin G
  •  go-up   go-down


89. Vajdic CM, Falster MO, de Sanjose S, Martínez-Maza O, Becker N, Bracci PM, Melbye M, Smedby KE, Engels EA, Turner J, Vineis P, Costantini AS, Holly EA, Kane E, Spinelli JJ, La Vecchia C, Zheng T, Chiu BC, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Cozen W, Grulich AE: Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res; 2009 Aug 15;69(16):6482-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis.
  • We performed a pooled analysis of data on atopic disease and risk of non-Hodgkin lymphoma (NHL) from 13 case-control studies, including 13,535 NHL cases and 16,388 controls.
  • Eczema was positively associated with lymphomas of the skin; misdiagnosis of lymphoma as eczema is likely, but progression of eczema to cutaneous lymphoma cannot be excluded.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 May;15(4):419-28 [15141141.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):316-27 [12915497.001]
  • [Cites] J Chronic Dis. 1978;31(9-10):619-24 [744792.001]
  • [Cites] Leuk Res. 1984;8(4):681-9 [6471900.001]
  • [Cites] Prev Med. 1987 Jan;16(1):96-106 [3823013.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1365-72 [17481729.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Allergy. 2008 Oct;63(10):1255-66 [18671772.001]
  • [Cites] Leuk Res. 1988;12(1):81-8 [3357350.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):451-5 [3383143.001]
  • [Cites] Leuk Res. 1989;13(6):465-72 [2770331.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Am J Epidemiol. 1992 Aug 1;136(3):287-95 [1415150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):533-6 [1302565.001]
  • [Cites] Eur Respir J. 1993 May;6(5):694-7 [8519380.001]
  • [Cites] Int J Epidemiol. 1993 Dec;22(6):976-82 [8144310.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] BMC Public Health. 2004 Nov 4;4:51 [15527506.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):133-42 [15617998.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):212-21 [15987724.001]
  • [Cites] Allergy. 2005 Sep;60(9):1098-111 [16076292.001]
  • [Cites] Allergy. 2005 Sep;60(9):1116-20 [16076294.001]
  • [Cites] Allergy. 2005 Oct;60(10):1280-6 [16134995.001]
  • [Cites] J Investig Allergol Clin Immunol. 2005;15(3):161-6 [16261950.001]
  • [Cites] Allergy. 2006 Mar;61(3):390-1 [16436152.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3124-32 [16395696.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1287-94 [16835325.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3028-33 [16945522.001]
  • [Cites] J Asthma. 2006 Dec;43(10):727-30 [17169822.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):158-66 [17227999.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):102-11 [17387295.001]
  • [Cites] Mol Immunol. 2007 Jul;44(14):3462-72 [17485116.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3527-37 [10556807.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]
  • [Cites] Eur Respir J. 2000 Sep;16(3):420-6 [11028654.001]
  • [Cites] Eur J Clin Nutr. 2001 Apr;55(4):298-304 [11360135.001]
  • [Cites] Cancer Causes Control. 2001 Apr;12(3):201-12 [11405325.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):401-7 [11927501.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):606-12 [12672680.001]
  • [Cites] Cancer. 1971 Jan;27(1):93-9 [5539630.001]
  • (PMID = 19654312.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA089745-01; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / CA089745-01; United States / NCI NIH HHS / CA / CA89745; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC67009; United States / NCI NIH HHS / CA / CA45614; United States / NCI NIH HHS / CA / K07 CA115687; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01 CA121195; United States / NCI NIH HHS / PC / PC67008; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / CA / CA92153; United States / NCI NIH HHS / CA / CA69269-02; United States / NCI NIH HHS / CA / CA87014; United States / NCI NIH HHS / CA / R01 CA069269-02; United States / NCI NIH HHS / CA / CA104682; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R01 CA062006; United States / NCI NIH HHS / PC / PC71105; United States / NCI NIH HHS / CA / CA092153-01A2; United States / NCI NIH HHS / CA / R01 CA104682; United States / NCI NIH HHS / PC / PC67010; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / CA104682-01; United States / NCI NIH HHS / CA / CA087014-01A1; United States / NCI NIH HHS / PC / PC65064; United States / NCI NIH HHS / CA / R01 CA087014; United States / NCI NIH HHS / CA / CA51086; United States / NCI NIH HHS / CA / R01 CA051086; United States / NCI NIH HHS / CA / R01 CA045614; United States / NCI NIH HHS / CA / R01 CA104682-01; United States / NCI NIH HHS / CA / R01 CA087014-01A1; United States / NCI NIH HHS / CA / R01 CA092153-01A2; United States / NCI NIH HHS / CA / R03 CA089745
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS128417; NLM/ PMC2758272
  •  go-up   go-down


90. Zelcer S, Chen B, Mangel J, Vujovic O, Thiessen-Philbrook HR, Reider M, Mahmud FH: Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation. J Cancer Surviv; 2010 Sep;4(3):218-24
MedlinePlus Health Information. consumer health - Vascular Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation.
  • BACKGROUND: Mediastinal radiation can accelerate atherosclerosis in Hodgkin lymphoma survivors (HLS), and early detection is optimal.
  • [MeSH-major] Endothelium, Vascular / physiopathology. Hodgkin Disease / radiotherapy. Mediastinal Neoplasms / radiotherapy. Survivors. Vascular Diseases / physiopathology
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Cross-Sectional Studies. Female. Humans. Male. Pilot Projects. Radiation Tolerance. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 2009 Jun;154(6):901-5 [19217124.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):541 [2926473.001]
  • [Cites] J Am Coll Cardiol. 2003 May 21;41(10):1761-8 [12767662.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1111-5 [1359209.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Pediatr. 2009 Nov;155(5):678-82 [19595374.001]
  • [Cites] Am Heart J. 2003 Jul;146(1):168-74 [12851627.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):881-9 [8960517.001]
  • [Cites] J Am Coll Cardiol. 2001 Dec;38(7):1843-9 [11738283.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):766-73 [8760008.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):51-62 [9488128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):897-906 [9369139.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] J Clin Oncol. 2014 Nov 10;32(32):3651-8 [25311218.001]
  • [Cites] Circulation. 2008 May 13;117(19):2467-74 [18458169.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1205-11 [7713783.001]
  • [Cites] J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41 [15582310.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Am Coll Cardiol. 2001 Mar 1;37(3):761-5 [11693749.001]
  • [Cites] Int J Cardiol. 1995 Mar 24;49(1):39-43 [7607765.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] Pediatr Diabetes. 2007 Aug;8(4):193-8 [17659060.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] Am J Med. 1981 Mar;70(3):519-30 [6782873.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):43-9 [17194904.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1387-92 [10364068.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):55-75 [12482572.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6):730-9 [14663774.001]
  • [Cites] Pediatrics. 1995 May;95(5):722-6 [7724311.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3991-4008 [17577017.001]
  • [Cites] J Hypertens. 2005 Feb;23(2):233-46 [15662207.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):620-4 [15825157.001]
  • [Cites] Am J Cardiol. 1987 Nov 1;60(13):1020-4 [3673902.001]
  • [Cites] Vasc Med. 2007 Feb;12 (1):13-6 [17451088.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):557-62 [18346515.001]
  • [Cites] Acta Paediatr Suppl. 2004 Dec;93(446):48-54 [15702670.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):355-63 [2261376.001]
  • [Cites] J Am Coll Cardiol. 1995 Nov 1;26(5):1235-41 [7594037.001]
  • (PMID = 20652436.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Zeh A, Bernstein A, Genest M, Held A, Hein W: [Cage failure following replacement of the third lumbar vertebral body in Hodgkin's disease]. Z Orthop Ihre Grenzgeb; 2006 May-Jun;144(3):328-31
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cage failure following replacement of the third lumbar vertebral body in Hodgkin's disease].
  • [Transliterated title] Cageversagen nach LWK3-Ersatz bei M. Hodgkin.
  • AIM: We present a case report and the histological analysis of cage failure following vertebral body replacement in Hodgkin's disease.
  • METHOD: In a 35-year-old patient with a single metastasis of Hodgkin's disease replacement of the third lumbar vertebral body (Harms-titanium-mesh-cage, DePuy Acromed, completely filled with autogenous spongiosa from the iliac crest) was performed.
  • [MeSH-major] Hodgkin Disease / surgery. Lumbar Vertebrae / surgery. Spinal Fusion / instrumentation. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Plates. Humans. Male. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821187.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Takahashi N, Ghazale AH, Smyrk TC, Mandrekar JN, Chari ST: Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas; 2009 Jul;38(5):523-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma.
  • OBJECTIVES: IgG4-associated systemic disease (ISD) is a multiorgan fibroinflammatory disorder whose pancreatic manifestation is called autoimmune pancreatitis (AIP).
  • We describe 3 patients who developed non-Hodgkin lymphoma during the follow-up of ISD.
  • We reviewed the medical records of all 111 patients to identify patients who developed non-Hodgkin lymphoma during the follow-up since their first presentation of ISD.
  • RESULTS: The 111 patients with ISD with or without AIP had 331 patient-years of observation during which 3 patients had a diagnosis of non-Hodgkin lymphoma 3 to 5 years after the diagnosis of ISD.
  • In these patients who later developed lymphoma, ISD involved the pancreas (AIP) in 2 and salivary gland in 1.
  • Non-Hodgkin lymphoma had extranodal involvement in all patients (liver [n = 2], adrenal glands [n=1], kidney [n= 1], and lung [n = 1]).
  • CONCLUSIONS: We report 3 cases of non-Hodgkin lymphoma that developed during the follow-up of ISD suggesting that patients with ISD may be at an increased risk of developing non-Hodgkin lymphoma.
  • [MeSH-major] Autoimmune Diseases / complications. Immunoglobulin G / immunology. Lymphoma, Non-Hodgkin / etiology. Pancreatitis / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors. Tomography, X-Ray Computed. Young Adult


93. Kumar L, Ganessan P, Ghosh I, Panda D, Gogia A, Mandhania S: Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome. Natl Med J India; 2010 Nov-Dec;23(6):330-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome.
  • BACKGROUND: We analysed data on patients of Hodgkin and non-Hodgkin lymphoma treated with high dose chemotherapy followed by autologous stem cell transplantation to determine the toxicity, pattern of infections and long-term outcome.
  • Before transplantation, 31 patients (70.5%) had chemosensitive disease and 13 (29.5%) had chemoresistant disease.
  • The rate of complete response was higher for patients with pre-transplant chemosensitive disease (23/31 [74.2%] v. 2/13 [15.4%], p < 0.001).
  • CONCLUSION: Patients with pre-transplant chemosensitive disease and those who achieved complete response following transplant had a significantly better chance of survival.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome


94. Pahwa P, McDuffie HH, Dosman JA, McLaughlin JR, Spinelli JJ, Robson D, Fincham S: Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides. J Occup Environ Med; 2006 Mar;48(3):264-74
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides.
  • OBJECTIVE: The objective of this study was to determine if there is an additional risk of developing Hodgkin lymphoma, multiple myeloma, or soft tissue sarcoma as a consequence of exposure to a combination of phenoxyherbicides, rubber gloves, DEET (N, N-diethyl-m-toluamide), and sunlight compared with each of the individual chemicals.
  • RESULTS: No additional risk from these combinations of exposures of developing these three types of tumor was found in contrast to non-Hodgkin lymphoma.
  • CONCLUSIONS: The mechanisms by which phenoxyherbicides contribute to the risk of multiple myeloma and non-Hodgkin lymphoma may be different.


95. Landgren O, Björkholm M, Montgomery SM, Hjalgrim H, Sjöberg J, Goldin LR, Askling J: Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma. Int J Cancer; 2006 Jan 15;118(2):449-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma.
  • Young-adult-onset (15-44 years of age) Hodgkin lymphoma (HL) is believed to arise as a consequence of late primary infection in susceptible individuals.
  • Cases with young-adult-onset HL were less likely to have a personal (OR =0.5, 95% CI 0.2-1.1) or family (OR =0.7, 95% CI 0.6-0.8) history of diabetes mellitus.
  • These findings suggests that characteristics of the immune system associated with conditions such as diabetes mellitus type I are of importance in the pathogenesis of young-adult-onset HL.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Diabetes Mellitus, Type 1 / genetics. Hodgkin Disease / etiology
  • [MeSH-minor] Adult. Age of Onset. Case-Control Studies. Female. Humans. Immune System / physiology. Male. Middle Aged. Odds Ratio. Pedigree. Risk Factors


96. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, Davis S, Severson RK, Rothman N, Chanock SJ, Hartge P: Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res; 2007 May 15;67(10):5042-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.
  • Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non-Hodgkin lymphoma (NHL) in a large pooled analysis.
  • We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma].
  • NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (OR(NHL), 2.1; 95% CI, 1.0-4.2) or the IL10 T3575A TA/AA genotype (OR(NHL), 1.6; 95% CI, 0.9-2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Interleukin-10 / genetics. Interleukin-10 / immunology. Male. Middle Aged. Polymorphism, Single Nucleotide. Risk Factors. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510437.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


97. Heran NS, Yong RL, Heran MS, Yip S, Fairholm D: Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report. J Neurosurg Spine; 2006 Jul;5(1):61-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report.
  • An intraoperative pathological examination determined the lesion to be a Hodgkin lymphoma.
  • To the authors' knowledge this is the first reported case of a presumed primary intradural extraarachnoid Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cervical Vertebrae. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850958.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Cil T, Altintaş A, Işikdoğan A, Paşa S, Bayan K, Batun S, Büyükbayram H: Screening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients. Turk J Gastroenterol; 2009 Jun;20(2):87-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients.
  • BACKGROUND/AIMS: Celiac disease is an abnormal T cell-mediated immune response against dietary gluten in genetically predisposed individuals.
  • The aim of our prospective study was to evaluate the frequency of Celiac disease in patients with lymphoma and to determine the usefulness of the anti-gliadin and anti-endomysial antibodies (EMA) for diagnosis of Celiac disease in this patient group.
  • METHODS: We studied 119 patients with previously or newly diagnosed non-Hodgkin's lymphoma and 60 patients with Hodgkin's lymphoma who presented at the hematology and medical oncology divisions of Dicle University Hospital in Turkey between December 2002 and January 2006.
  • Serological screening for Celiac disease was performed in all patients by searching for serum anti-gliadin immunoglobulin A and immunoglobulin G, and EMA immunoglobulin A and immunoglobulin G.
  • RESULTS: In the Hodgkin's lymphoma group, anti-gliadin immunoglobulin A was detected in 9 (15%) patients (3 male, 6 female), and antigliadin immunoglobulin G was detected in 21 (35%) patients (15 male, 6 female).
  • In the non-Hodgkin's lymphoma group, antigliadin immunoglobulin A was detected in 6 (5%) patients (2 M male 4 female), and anti-gliadin immunoglobulin G was detected in 30 (25.2%) patients (18 male, 12 female).
  • EMA immunoglobulin A and immunoglobulin G were not detected in the Hodgkin's lymphoma and non-Hodgkin's lymphoma groups.
  • CONCLUSIONS: Our report is the first to describe the frequency of Celiac disease in patients with lymphoma in the southeast region of Turkey.
  • In our study, there was no evidence that Celiac disease is a pre-malignant condition for lymphoma.
  • Serological screening for Celiac disease in lymphoma patients does not seem to be necessary.
  • [MeSH-major] Celiac Disease / epidemiology. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Autoantibodies / blood. Comorbidity. Female. Gliadin / blood. Gliadin / immunology. Hospitals, University / statistics & numerical data. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Incidence. Male. Mass Screening. Middle Aged. Turkey / epidemiology. Young Adult


99. Mrzljak A, Gasparov S, Kardum-Skelin I, Colic-Cvrlje V, Ostojic-Kolonic S: Febrile cholestatic disease as an initial presentation of nodular lymphocyte-predominant Hodgkin lymphoma. World J Gastroenterol; 2010 Sep 21;16(35):4491-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile cholestatic disease as an initial presentation of nodular lymphocyte-predominant Hodgkin lymphoma.
  • Febrile cholestatic liver disease is an extremely unusual presentation of Hodgkin lymphoma (HL).
  • [MeSH-major] Cholestasis. Fever. Hodgkin Disease / complications. Hodgkin Disease / physiopathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Mar 15;71(6):2062-71 [8443755.001]
  • [Cites] Am J Gastroenterol. 1992 Sep;87(9):1194-5 [1519580.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet. 2006 Mar 25;367(9515):1028 [16564367.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Sep;11(9):1055-8 [10503847.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):196-201 [18227720.001]
  • [Cites] Acta Oncol. 2008;47(5):962-70 [17906981.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Mar;14(3):323-7 [11953700.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):489-95 [15087668.001]
  • [Cites] Dig Liver Dis. 2004 Oct;36(10):691-3 [15506670.001]
  • [Cites] Cancer. 1971 Nov;28(5):1335-42 [5125679.001]
  • [Cites] Q J Med. 1979 Jan;48(189):137-50 [482587.001]
  • [Cites] J Surg Oncol. 1980;14(2):111-23 [7392635.001]
  • [Cites] J Clin Gastroenterol. 1986 Jun;8(3 Pt 1):304-7 [3734366.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):257-68 [3317862.001]
  • [Cites] N Engl J Med. 1988 Jan 28;318(4):214-9 [3336412.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1303-9 [2769329.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2121-6 [2804900.001]
  • [Cites] Gut. 1991 Aug;32(8):959-62 [1885082.001]
  • [Cites] Ann Hematol. 1996 Jun;72(6):357-60 [8767104.001]
  • (PMID = 20845519.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2941075
  •  go-up   go-down


100. Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP: Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol; 2007 Mar;136(5):752-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
  • A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation.
  • Subgroup analysis showed overall response rates of 93.1% for HD with a 5-year OS and EFS of 62% and 52% respectively, while NHL showed response rates of 78.0% with 5-year OS and EFS of 50% and 39% respectively.
  • We conclude that IVE has a high response rate across a range of refractory and relapsed lymphoma with acceptable toxicity and excellent PBSC mobilising characteristics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Epirubicin / adverse effects. Epirubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Male. Middle Aged. Neutropenia / chemically induced. Peripheral Blood Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313378.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IEV protocol
  •  go-up   go-down






Advertisement